[Azidothymidine in the management of immune deficiency complex].
The nucleoside-analogue azidothymidine is the first effective drug in the management of HIV-infection although it is not a causal therapy. Azidothymidine increases the life-span of the HIV-positive patients, decreases the incidence of opportunistic infections and enhances the quality of life. The current recommendations is to use the drug at a dose of 500 mg daily in persons with CD4+ counts of less than 500. The (unwanted) side-effects are less prominent at this lower dose. Although there is a very significant research work all over the world for newer drugs for HIV-therapy, it seems that for the foreseeable future azidothymidine will remain the cornerstone of antiretroviral therapy.
Bálint Gábor
S
S
Szent-Györgyi Albert Orvostudományi Egyetem Ideg- és Elmegyógyászati Klinikájának Klinikai Farmakológiai Laboratóriuma, Szeged.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D011379:Prognosis; D015215:Zidovudine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D015215:Zidovudine
Azidotimidin a szerzett immunhiányos tünetegyüttes gyógykezelésében.